Evidence-Based Medicine Guidelines
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Second or Third Additional Chemotherapy Drug for Non-small Cell Lung Cancer in Patients With Advanced Disease." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/452321/all/Second_or_third_additional_chemotherapy_drug_for_non_small_cell_lung_cancer_in_patients_with_advanced_disease.
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/452321/all/Second_or_third_additional_chemotherapy_drug_for_non_small_cell_lung_cancer_in_patients_with_advanced_disease. Accessed April 1, 2023.
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/452321/all/Second_or_third_additional_chemotherapy_drug_for_non_small_cell_lung_cancer_in_patients_with_advanced_disease
Second or Third Additional Chemotherapy Drug for Non-small Cell Lung Cancer in Patients With Advanced Disease [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 April 01]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/452321/all/Second_or_third_additional_chemotherapy_drug_for_non_small_cell_lung_cancer_in_patients_with_advanced_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease
ID - 452321
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/452321/all/Second_or_third_additional_chemotherapy_drug_for_non_small_cell_lung_cancer_in_patients_with_advanced_disease
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
